Biogen Inc. said it found that patients treated with the company's multiple-sclerosis therapies achieved an antibody response to Covid-19 vaccination.
The company Wednesday said preliminary results from a new analysis suggest that anti-CD20 and sphingosine 1-phosphate, or S1P, therapies may reduce the antibody response to Covid-19 vaccination. For all other classes evaluated in the analysis--including the broad range of MS therapies offered by Biogen--the antibody response to vaccination is consistent with the response of patients not being treated with an MS disease-modifying therapy, the company said.
Biogen said researchers looked at blood samples from 322 participants 28 to 90 days after their last Covid-19 vaccine dose, using data from a company-sponsored network in the U.S., Germany and Spain. About 92% of participants in the analysis received an mRNA vaccine, the company said.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.